Forest Laboratories

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

Retrieved on: 
Monday, March 18, 2024
Psychiatry, Growth, Neurology, Sunovion, Business administration, Cornell University, Patient, CNS, SNDX, Cancer, Marketing, Forest Laboratories, Allergan, Therapy, Pharmaceutical industry

WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately. Mr. Closter will lead the Company's commercial strategy and operations, including marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal reasons.

Key Points: 
  • WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.
  • "Steven Closter is an accomplished leader with a proven track record of building commercial teams, leading successful product launches and delivering growth across a broad range of therapeutic areas," said Michael A. Metzger, Chief Executive Officer.
  • Mr. Closter brings to Syndax over 30 years of commercial experience, which included the oversight of over a dozen product launches and indication expansions.
  • Mr. Metzger added: "We thank Steve Sabus for his contributions to Syndax and for his assistance in seamlessly transitioning the role to Steven Closter.

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Psychopharmacology, ACAD, Development, Psychiatry, Patient, Research, Forest Laboratories, Teva Pharmaceuticals, Humour, Friends, Rett syndrome, University, Medicine, Public health, Drug development, Caregiver, Johnson & Johnson, Birmingham School of Law, Private sector, Pharmaceutical industry

(Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H.

Key Points: 
  • (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H.
  • “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years.
  • Serge transitioned to the private sector as a medical officer at UCB Pharma and quickly rose through the organization to Vice President of U.S. Clinical Development.
  • He went on to hold leadership positions in research and development at Johnson & Johnson, Neurogen Pharmaceuticals, Forest Laboratories, Teva Pharmaceuticals, and Alkermes.

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Finance, Health, Professional Services, Asset Management, Ionis Pharmaceuticals, Science, Cure, Drug discovery, Partner, Pramipexole, UC, Juno Therapeutics, Forest Laboratories, DSM-IV codes, Heart, Therapy, Memantine, Growth, Central nervous system, Patient, Organization, Harvard Medical School, Biogen, University of California, Irvine, Pharmaceutical industry

Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.

Key Points: 
  • Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.
  • and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
  • It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.
  • More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures.

AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Forest Laboratories, Seres, U.S. Commercial Service in Taiwan, Merck, Doctor of Philosophy, Development, Senior, Relay, Shire, Marketing, Lung cancer, Cancer, Therapy, ARIAD Pharmaceuticals, David Berry (inventor), Regulatory affairs, Pharmaceutical industry, Takeda

AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.

Key Points: 
  • AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.
  • Amy joins AnHeart with more than 20 years of commercial experience in the pharmaceutical and biotech industry.
  • Amy will lead commercial strategy for AnHeart’s investigational precision therapies in the United States, focusing initially on preparing AnHeart for the commercial launch of taletrectinib.
  • Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.

OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs

Retrieved on: 
Wednesday, September 20, 2023
University, Schering-Plough, Pharming, Pharmacovigilance, NDA, Cancer, Novo Nordisk, Attention, Rutgers University, AML, Forma, Acquisition, Olutasidenib, Patient, Forest Laboratories, Entrepreneurship, Regulatory affairs, FDA, Medical device

BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Ann Howell as Vice President of Regulatory Affairs.

Key Points: 
  • BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Ann Howell as Vice President of Regulatory Affairs.
  • Dr. Howell brings an abundance of experience managing regulatory affairs activities for both small and large biopharmaceutical companies, with global regulatory responsibilities across a variety of therapeutic areas, including oncology.
  • “We are delighted to welcome Ann to the OnKure team,” said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure.
  • “Ann has an impressive background in leading the regulatory strategies for numerous product developments and subsequent NDA submissions, in addition to expertise overseeing global regulatory interactions for oncology development projects.

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Retrieved on: 
Wednesday, September 6, 2023
Biotechnology, Health, Professional Services, Pharmaceutical, Legal, Archives of Oral Biology, DSM-IV codes, Patent, A-T, College, Therapy, Western New England University, Senior, New York State Bar Association, Stony Brook University, Research, IP, CNS, Acquisition, AbbVie, Forest Laboratories, Patient, Pathology, Forest, College of Wooster, Pharmaceutical industry, Quince, Chemistry

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.
  • Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “Charles is a valuable addition to our management team.
  • His considerable expertise will help enhance efficiency and effectiveness across our research programs and business operations.
  • Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions.

Allay Therapeutics Appoints Nicole Vitullo to Board of Directors

Retrieved on: 
Wednesday, September 6, 2023
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nicole, Actavis, University, Esperion Therapeutics, Transformation/transcription domain-associated protein, MBA, Cubist Pharmaceuticals, Onyx Pharmaceuticals, Esperies, Celgene, Partner, Patient, Forest Laboratories, Arboretum, Pain management, Alexion, Jazz Pharmaceuticals, David Allais, Mathematics, Therapy, Caregiver, Pharmaceutical industry

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

Key Points: 
  • Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
  • “We’re thrilled to have Nicole join the Allay board and appreciate the continued support of Arboretum Ventures as we work to change the pain management paradigm and dramatically improve the post-surgical recovery experience for patients,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics.
  • Nicole currently serves on the board of Esperion Therapeutics and Hinge Bio Inc.
  • Her past board memberships include numerous companies that have entered transactions, including Achillion Pharmaceuticals (Alexion), Calixa Therapeutics (Cubist Pharmaceuticals), Celator Pharmaceuticals (Jazz Pharmaceuticals), Cerexa (Forest Laboratories), Durata Therapeutics (Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (Celgene).

Dunad Therapeutics Announces Appointment of Chief Business Officer

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Pharmaceutical, Health, Therapy, Pharmacia, Business, Massachusetts Innovation & Technology Exchange, CNS, Assistant, Regenerative medicine, Forest Laboratories, Pharmaceutical industry

Dunad Therapeutics , a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Jonathan Garen as its Chief Business Officer.

Key Points: 
  • Dunad Therapeutics , a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Jonathan Garen as its Chief Business Officer.
  • "Jonathan is a proven leader in business development and corporate strategy, with a strong track record of building high value partnerships,” said Pearl Huang, Chief Executive Officer of Dunad Therapeutics.
  • “His expertise will bring immense value to Dunad as we expand the role of covalent small molecules to create first-and best-in class therapeutics that access previously undruggable or historically challenging targets.”
    Mr. Garen joins Dunad with more than 25 years of operational experience in business development and pipeline and corporate strategy, including serving as Chief Business Officer of Nocion Therapeutics, Inc., where he led pipeline, partnering and commercial strategy.
  • Mr. Garen was also a member of the Board of the Alliance for Regenerative Medicine, an industry organization focused on genetic medicines.

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

Retrieved on: 
Wednesday, April 12, 2023
IPO, University, Employment, GBA1, RSU, Therapy, Partnership, Biotechnology, Synthetic biological circuit, History, DSM-IV codes, Patient, Forest Laboratories, AbbVie, Drug discovery, Inducement, Pharmaceutical industry, Security (finance)

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately.

Key Points: 
  • BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately.
  • “I am thrilled to be joining the Gain team at this exciting time in the Company’s development,” said Mr. Ballantyne, Chief Financial Officer.
  • I also look forward to helping Gain maximize the potential of the SEE-Tx® drug discovery platform, which transforms drug discovery by enabling the identification of novel allosteric small molecule therapeutics across the full spectrum of therapeutic areas.”
    “We are delighted to welcome Evan Ballantyne as our new Chief Financial Officer,” said Matthias Alder, Chief Executive Officer at Gain Therapeutics.
  • Most recently he was Chief Financial Officer of OncXerna Therapeutics, Inc., where he helped raise $30 million in an equity financing round.

Biogen Appoints Chuck Triano as Head of Investor Relations

Retrieved on: 
Tuesday, March 14, 2023
Research, Biotechnology, Therapy, University, Forest Laboratories, BIIB, Senior, Pfizer, Management, Biogen

CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023.

Key Points: 
  • CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023.
  • Prior to joining Xalud Therapeutics, Mr. Triano served as Senior Vice President of Investor Relations at Pfizer for over a decade, where he was responsible for all global investor relations functions, as well as operations planning and analysis.
  • Previously, he served as the Vice President of Investor Relations at Forest Laboratories, where he initiated the company’s first formal investor relations and corporate communications program.
  • Mike Hencke, Executive Director, Investor Relations, and the Investor Relations team will report to Mr. Triano.